|
Objective To evaluate the molecular targeted therapies (molecular targeted therapeutic drugs, MTTD) and interferon (interferon-α, INF-α) treatment of metastatic renal cell carcinoma of efficacy and adverse reactions , provide the basis for clinical choice . Method to develop a search strategy , electronic retrieval from 2000 to 2010 . Database ( Wanfang Database ) , China Academic Journal (CNKI), Science and Technology of China Academic Journal Database ( VIP ) , the Medline database , Cochrane Library database ( 4 , 2010 ) the inclusion and exclusion criteria , screening About MTTD and IFN-α in the treatment of metastatic renal cell carcinoma RCTs , the use of Cochrane systematic review of the principles and methods of evaluation of research quality , using RevMan5.1 statistical analysis . The results met the inclusion criteria RCTs 7 , 3495 cases cases . Meta-analysis results showed that : ( 1) compared with IFN-α , with sorafenib or sunitinib treatment of metastatic renal cell carcinoma has a higher objective response rate ( OR = 4.17,95 % CI [ 2.04,8.53 ] , P lt ; 0.0001 ) , more effective control of disease progression (OR = 0.29, 95 % CI [ 0.21,0.36 ] , P lt; 0.0001 ) , without increasing adverse events (OR = 1.15, 95% CI [ 0.80 , 1.63 ] , P = 0.45 ) ; (2 ) compared with IFN-α , bevacizumab plus IFN-α treatment of metastatic renal cell carcinoma has a higher objective response rate ( OR = 3.20,95 % CI [ 2.29,4.47 ] , P lt ; 0.00001 ) , able to effectively control the disease progression (OR = 0.64, 95% CI [ 0.52,0.78 ] , P lt; 0.00001 ) , accompanied by many of the adverse events (OR = 1.40,95% CI [1.04,1.88 Conclusion 1 . Molecular targeted drugs can effectively control the progress of metastatic renal cell carcinoma , improve objectively efficiency ; 2 . Molecularly targeted drugs with IFN-α used in combination , may increase the incidence of serious adverse reactions ; 3 . Clinical drug selection should focus on the condition of the patient weigh be selected.
|